Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies

Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies

As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise...

Full description

Bibliographic Details
Main Authors: Alimuddin Zumla, Fu-Sheng Wang, Giuseppe Ippolito, Nicola Petrosillo, Chiara Agrati, Esam I. Azhar, Chao Chang, Sherif A. El-Kafrawy, Mohamed Osman, Laurence Zitvogel, Peter R. Galle, Franco Locatelli, Ellen Gorman, Carlos Cordon-Cardo, Cecilia O’Kane, Danny McAuley, Markus Maeurer
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:International Journal of Infectious Diseases
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971220303477

Internet

http://www.sciencedirect.com/science/article/pii/S1201971220303477

Similar Items